AU6572194A - Defective recombinant adenoviruses for gene therapy of tumours - Google Patents

Defective recombinant adenoviruses for gene therapy of tumours

Info

Publication number
AU6572194A
AU6572194A AU65721/94A AU6572194A AU6572194A AU 6572194 A AU6572194 A AU 6572194A AU 65721/94 A AU65721/94 A AU 65721/94A AU 6572194 A AU6572194 A AU 6572194A AU 6572194 A AU6572194 A AU 6572194A
Authority
AU
Australia
Prior art keywords
tumours
defective recombinant
gene therapy
recombinant adenoviruses
defective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU65721/94A
Other versions
AU696245B2 (en
Inventor
Hedi Haddada
Evelyne May
Michel Perricaudet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Rhone Poulenc Rorer SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer SA filed Critical Rhone Poulenc Rorer SA
Publication of AU6572194A publication Critical patent/AU6572194A/en
Application granted granted Critical
Publication of AU696245B2 publication Critical patent/AU696245B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82Translation products from oncogenes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/76Viruses; Subviral particles; Bacteriophages
    • A61K35/761Adenovirus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1758Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals p53
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10041Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10211Aviadenovirus, e.g. fowl adenovirus A
    • C12N2710/10241Use of virus, viral particle or viral elements as a vector
    • C12N2710/10243Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Defective recombinant adenovirus contains a heterologous DNA sequence (I), the expression of which in a target cell contributes to the inhibition of cell division.
AU65721/94A 1993-04-22 1994-04-15 Defective recombinant adenoviruses for gene therapy of tumours Expired AU696245B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9304745 1993-04-22
FR9304745A FR2704234B1 (en) 1993-04-22 1993-04-22 RECOMBINANT VIRUSES, PREPARATION AND USE IN GENE THERAPY.
PCT/FR1994/000421 WO1994024297A1 (en) 1993-04-22 1994-04-15 Defective recombinant adenoviruses for gene therapy of tumours

Publications (2)

Publication Number Publication Date
AU6572194A true AU6572194A (en) 1994-11-08
AU696245B2 AU696245B2 (en) 1998-09-03

Family

ID=9446321

Family Applications (1)

Application Number Title Priority Date Filing Date
AU65721/94A Expired AU696245B2 (en) 1993-04-22 1994-04-15 Defective recombinant adenoviruses for gene therapy of tumours

Country Status (15)

Country Link
EP (2) EP0695360B1 (en)
JP (1) JPH08508879A (en)
AT (1) ATE332386T1 (en)
AU (1) AU696245B2 (en)
DE (1) DE69434781T2 (en)
DK (1) DK0695360T3 (en)
ES (1) ES2264123T3 (en)
FI (1) FI118011B (en)
FR (1) FR2704234B1 (en)
HU (1) HU220346B (en)
NO (1) NO321454B1 (en)
NZ (1) NZ265306A (en)
PT (1) PT695360E (en)
WO (1) WO1994024297A1 (en)
ZA (1) ZA942778B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU698437B2 (en) * 1993-10-29 1998-10-29 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus methods and compositions
US7256181B2 (en) 1997-08-29 2007-08-14 Biogen Idec Ma Inc. Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992015680A1 (en) 1991-03-06 1992-09-17 Board Of Regents, The University Of Texas System Methods and compositions for the selective inhibition of gene expression
US5747469A (en) * 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
FR2717496B1 (en) * 1994-03-18 1996-04-12 Rhone Poulenc Rorer Sa Recombinant viruses, preparation and use in gene therapy.
FR2705686B1 (en) * 1993-05-28 1995-08-18 Transgene Sa New defective adenoviruses and corresponding complementation lines.
US6682728B1 (en) * 1993-10-13 2004-01-27 The United States Of America As Represented By The Department Of Health And Human Services Efficient and selective adenoviral-mediated gene transfer into vascular neointima
ATE314482T1 (en) * 1993-10-25 2006-01-15 Canji Inc RECOMBINANT ADENOVIRUS VECTOR AND METHOD OF USE
TW442569B (en) * 1993-10-25 2001-06-23 Canji Inc Recombinant adenoviral vector
US6210939B1 (en) 1993-10-25 2001-04-03 Canji, Inc. Recombinant adenoviral vector and methods of use
FR2717497B1 (en) * 1994-03-18 1996-04-12 Rhone Poulenc Rorer Sa Recombinant viruses, preparation and use in gene therapy.
FR2717495B1 (en) * 1994-03-18 1996-04-12 Rhone Poulenc Rorer Sa Recombinant viruses, preparation and use in gene therapy.
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
CA2192442C (en) 1994-06-10 2007-09-25 Imre Kovesdi Complementary adenoviral vector systems and cell lines
FR2725213B1 (en) * 1994-10-04 1996-11-08 Rhone Poulenc Rorer Sa VIRAL VECTORS AND USE IN GENE THERAPY
FR2726285B1 (en) * 1994-10-28 1996-11-29 Centre Nat Rech Scient ADENOVIRUSES CONTAINING VIABLE CONTAMINANT PARTICLES, PREPARATION AND USE
US7097972B1 (en) 1995-02-13 2006-08-29 Regents Of The University Of Michigan Method and composition for regulating apoptosis
US6015665A (en) * 1995-02-13 2000-01-18 The Regents Of The University Of Michigan Method and composition for regulating apoptosis
US6060238A (en) * 1995-02-13 2000-05-09 The Regents Of The University Of Michigan Method and composition for regulating apoptosis
FR2730637B1 (en) 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa PHARMACEUTICAL COMPOSITION CONTAINING NUCLEIC ACIDS, AND USES THEREOF
WO1996025507A2 (en) * 1995-02-17 1996-08-22 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methods of preparation and use of recombinant adenoviral vectors
US5637456A (en) * 1995-02-17 1997-06-10 The University Of Texas, Board Of Regents Rapid test for determining the amount of functionally inactive gene in a gene therapy vector preparation
US5707618A (en) * 1995-03-24 1998-01-13 Genzyme Corporation Adenovirus vectors for gene therapy
US7807783B1 (en) 1995-04-03 2010-10-05 The Regents Of The University Of Michigan Methods and compositions for regulating FAS-associated apoptosis
US6747138B1 (en) 1995-04-03 2004-06-08 Regents Of The University Of Michigan Methods and compositions for regulating Fas-associated apoptosis
US6783980B2 (en) 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
IL122614A0 (en) 1995-06-15 1998-08-16 Introgene Bv Packaging systems for human recombinant adenovirus to be used in gene therapy
US6482803B1 (en) 1995-09-01 2002-11-19 Board Of Regents, The University Of Texas System Modification of mutated P53 gene in tumors by retroviral delivery of ribozyme A
US7087582B1 (en) 1995-09-26 2006-08-08 Regents Of The University Of Michigan Combination for site-specifically transforming cells in vivo comprising a double-balloon catheter and nucleic acid comprising a gene encoding P21
US6054467A (en) * 1996-07-05 2000-04-25 Sidney Kimmel Cancer Center Down-regulation of DNA repair to enhance sensitivity to P53-mediated apoptosis
US5958892A (en) 1996-07-30 1999-09-28 Board Of Regents, The University Of Texas System 2-methoxyestradiol-induced apoptosis in cancer cells
US6113913A (en) 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
FR2790484B1 (en) 1999-03-01 2003-01-03 Michel Marcel Andre Loiselet FERMENTING MIXERS, PROVIDED WITH INNOVATIVE DEVICES IN THE MATERIAL, FOR THE MIXING OF VISCO-ELASTIC PASTA AND THE PRODUCTION OF PASTA LEAVEN
FR2829136B1 (en) 2001-08-29 2006-11-17 Aventis Pharma Sa LIPID DERIVATIVES OF AMINOGLYCOSIDES
US20030158112A1 (en) 2002-02-15 2003-08-21 Johns Hopkins University School Of Medicine Selective induction of apoptosis to treat ocular disease
EP2331071A1 (en) 2008-09-05 2011-06-15 Institut National De La Sante Et De La Recherche Medicale Novel multimodular assembly useful for intracellular delivery

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE237694T1 (en) * 1991-08-20 2003-05-15 Us Gov Health & Human Serv ADENOVIRUS-MEDIATED GENE TRANSFER INTO THE GASTROINTESTINAL TRACT
FR2688514A1 (en) * 1992-03-16 1993-09-17 Centre Nat Rech Scient Defective recombinant adenoviruses expressing cytokines and antitumour drugs containing them
GB9223084D0 (en) * 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU698437B2 (en) * 1993-10-29 1998-10-29 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus methods and compositions
US7256181B2 (en) 1997-08-29 2007-08-14 Biogen Idec Ma Inc. Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta

Also Published As

Publication number Publication date
HU220346B (en) 2001-12-28
ATE332386T1 (en) 2006-07-15
HU9503035D0 (en) 1995-12-28
EP1652931A3 (en) 2006-05-17
FI118011B (en) 2007-05-31
PT695360E (en) 2006-09-29
DK0695360T3 (en) 2006-11-13
FR2704234B1 (en) 1995-07-21
DE69434781D1 (en) 2006-08-17
FR2704234A1 (en) 1994-10-28
NO954132D0 (en) 1995-10-17
FI954966A0 (en) 1995-10-18
HUT73464A (en) 1996-08-28
JPH08508879A (en) 1996-09-24
WO1994024297A1 (en) 1994-10-27
NZ265306A (en) 1997-10-24
DE69434781T2 (en) 2007-06-14
ES2264123T3 (en) 2006-12-16
NO954132L (en) 1995-10-17
ZA942778B (en) 1995-01-09
EP1652931A2 (en) 2006-05-03
EP0695360A1 (en) 1996-02-07
AU696245B2 (en) 1998-09-03
EP0695360B1 (en) 2006-07-05
FI954966A (en) 1995-10-18
NO321454B1 (en) 2006-05-15

Similar Documents

Publication Publication Date Title
AU6572194A (en) Defective recombinant adenoviruses for gene therapy of tumours
MX9704552A (en) Cells for the production of recombinant adenoviruses.
MX9709549A (en) Recombinant adenoviruses, use thereof for preparing aavs, complementary cell line, and pharmaceutical compositions containing said adenoviruses.
ATE295739T1 (en) ADENOVIRAL VECTORS INCLUDING A PROSTATE SPECIFIC ANTIGEN (PSA) ßRESPONSE ELEMENTß
CA2153068A1 (en) Enhancer sequence for modulating expression in epithelial cells
MX9603002A (en) Method for preparing recombinant adeno-associated viruses (aav), and uses thereof.
AU7264694A (en) Defective adenovirus vectors and use thereof in gene therapy
WO1996007734A3 (en) Recombinant adenovirus comprising a chimeric penton base protein
NZ334034A (en) Use of a melanoma differentiation associated gene (mda-7) for reversing a cancerous phenotype
EP1637608A3 (en) Recombinant adenoviral vector and methods of use
IL136407A0 (en) Method for the production of glycerol by recombinant organisms
ZA9710199B (en) Method for the production of glycerol by recombinant organisms
AU4723596A (en) Method for preparing a recombinant adenovirus genome
NZ510356A (en) Molecules designated LDCAM
EP1007537A4 (en) Receptor protein designated 2f1
AU7155296A (en) Interleukin-19
EP0828003A3 (en) Human serine protease
CA2234263A1 (en) Pharmaceutical composition for treating papillomavirus tumours and infection
MX9601368A (en) Gene therapy for restenosis using an adenoviral vector.
AU8147194A (en) Recombinant adenoviruses for gene therapy in cancers
AU4368299A (en) Self-deleting vectors for cancer therapy
AU3525095A (en) Deffective recombinant adenoviruses with inactivated iva2 gene
PT1212428E (en) REDIRECTION OF THE EXPRESSION OF HERPES RANGE 34.5 GENE THROUGH A SPECIFIC CELL AND / OR SPECIFIC TUMOR PROMOTER
CA2218129A1 (en) Chimeric mcp and daf proteins with cell surface localizing domain
WO1996038556A3 (en) Deltap62, variants thereof, amino acid sequences coding therefor and their uses in gene therapy for cancer